| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
8.95(B) |
| Last
Volume: |
2,452,559 |
Avg
Vol: |
1,930,580 |
| 52
Week Range: |
$51.95 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
83,112 |
108,398 |
168,494 |
290,334 |
| Total Sell Value |
$4,965,701 |
$6,570,910 |
$11,439,131 |
$18,676,003 |
| Total People Sold |
10 |
10 |
11 |
11 |
| Total Sell Transactions |
43 |
52 |
62 |
100 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cole G Bradley |
General Manager - Diagnostics |
• – – |
2020-01-16 |
4 |
AS |
$90.30 |
$903,000 |
D/D |
(10,000) |
8,653 |
|
-10% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2019-12-16 |
4 |
OE |
$13.96 |
$199,992 |
D/D |
11,440 |
950,466 |
|
- |
|
| Cole G Bradley |
General Manager - Diagnostics |
• – – |
2019-12-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,334 |
18,653 |
|
- |
|
| Cole G Bradley |
General Manager - Diagnostics |
• – – |
2019-11-21 |
4 |
AS |
$80.38 |
$2,251,926 |
D/D |
(28,016) |
30,987 |
|
- |
|
| Casdin Eli |
Director |
– • – |
2019-11-08 |
4 |
A |
$0.00 |
$0 |
I/I |
450 |
225 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2019-10-30 |
4 |
A |
$60.60 |
$6,666 |
D/D |
110 |
59,109 |
|
- |
|
| Johnson Scott C. |
SVP - Research and Development |
• – – |
2019-09-12 |
4 |
AS |
$108.63 |
$383,138 |
D/D |
(3,527) |
12,311 |
|
- |
|
| Johnson Scott C. |
SVP - Research and Development |
• – – |
2019-09-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
15,838 |
|
- |
|
| Carey Thomas D. |
Director |
– • – |
2019-07-31 |
4 |
AS |
$114.99 |
$1,176,487 |
D/D |
(10,000) |
34,181 |
|
- |
|
| Napier Katherine S |
Director |
– • – |
2019-07-31 |
4 |
AS |
$117.93 |
$205,670 |
D/D |
(1,744) |
77,513 |
|
- |
|
| Levangie Daniel J |
Director |
– • – |
2019-07-31 |
4 |
AS |
$114.83 |
$5,012,398 |
D/D |
(42,607) |
12,458 |
|
- |
|
| Levangie Daniel J |
Director |
– • – |
2019-07-31 |
4 |
OE |
$3.43 |
$226,421 |
D/D |
42,607 |
55,065 |
|
- |
|
| Wyzga Michael S |
Director |
– • – |
2019-07-31 |
4 |
AS |
$117.93 |
$589,650 |
D/D |
(5,000) |
8,913 |
|
- |
|
| Wyzga Michael S |
Director |
– • – |
2019-07-31 |
4 |
OE |
$26.98 |
$67,450 |
D/D |
2,500 |
13,913 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2019-07-31 |
4 |
AS |
$117.93 |
$331,147 |
D/D |
(2,808) |
34,440 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2019-07-30 |
4 |
AS |
$105.60 |
$1,039,632 |
D/D |
(9,845) |
49,917 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2019-07-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,750 |
59,762 |
|
- |
|
| Slavitt Andrew M |
Director |
– • – |
2019-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,500 |
|
- |
|
| Levangie Daniel J |
Director |
– • – |
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,784 |
12,458 |
|
- |
|
| Wyzga Michael S |
Director |
– • – |
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,801 |
11,413 |
|
- |
|
| Slavitt Andrew M |
Director |
– • – |
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
5,387 |
5,387 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,155 |
37,248 |
|
- |
|
| Sebelius Kathleen |
Director |
– • – |
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,981 |
8,200 |
|
- |
|
| Carey Thomas D. |
Director |
– • – |
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,698 |
44,181 |
|
- |
|
| Napier Katherine S |
Director |
– • – |
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,155 |
79,257 |
|
- |
|
777 Records found
|
|
Page 17 of 32 |
|
|
1.57 (3.02%) 
